CML clonal evolution with resistance to single agent imatinib therapy

Clinical and Laboratory Haematology

Volumn 27, Issue 5, 2005, Pages 347-349

  Swords, R ^a,b   Quinn, J ^a   Fay, M ^a   O'Donnell, R ^a   Goldman, J ^a   Murphy, P T ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b LETTERKENNY GENERAL HOSPITAL   (Ireland)

Author keywords

Chronic myeloid leukaemia; Clonal evolution; Imatinib; Philadelphia chromosome; Resistance

Indexed keywords

ALPHA INTERFERON; CYTARABINE; HYDROXYUREA; IMATINIB;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLONOGENESIS; CYTOGENETICS; DRUG EFFICACY; HUMAN; LEUKEMIA REMISSION; MALE; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TRISOMY 8;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; CYTARABINE; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; TREATMENT FAILURE; TRISOMY;

EID: 26044474546     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2005.00721.x     Document Type: Article

References (12)

1. Branford S., Zbigniew R., Walsh S., Parkinson L, Grigg A., Szer J., Taylor K., Hermann R., Seymour J.F., Arthur C., Joske D., Lynch K. & Hughes T. (2003) Detection of BCR-ABL mutations in patients with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P Loop) are associated with a poor prognosis. Blood 102, 276-283.
2. Cortes J.E., Talpaz M., Giles F., O'Brien S., Rios M.B., Shan J., Garcia-Manero G., Faderi S., Thomas D.A., Wierda W., Farrogoli A., Jeha S. & Kantarjan H.M. (2003) Prognostic significance of cytogenetic cloncal evolution in patients with chronic myeloid leukaemia on imatinib mesylate therapy. Blood 101, 3794-3800.
3. Golemovic M., Verstovsek S., Giles F., Cortes J., Manshouri T., Manley P.W., Mestan J., Dugan M., Alland L., Griffin J.D., Arlinghaus R.B., Sun T., Kantarjian H. & Beran M. (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11, 4941-4947.
4. Kindler T., Breitenbuecher F., Kasper S., Stevens T., Carius B., Gschaidmeier H., Haber C. & Fischer T. (2003) In BCR-ABL positive cells, STAT-5 tyrosine-phosphorylation integrates sgnals induced by imatinib mesylate and Ara-C. Leukemia 17, 999-1009.
5. La Rosee P., Johnson K., Corsba A.S., Stoffregen E.P., Moseson E.M., Willis S., Mauro M.M., Melo J.V., Deininger M.W. & Druker B.J. (2004) In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib resistant Bcr-Abl positive cells. Blood 103, 208-215.
6. Marktel S., Marin D., Foot N., Szyolo R., Bua M., Karadimitris A., Demelo V.A., Kotzampaltiris P., Pazzi F., Rahemtulla A., Olavarraia E., Apperly J.F. & Goldman J.M. (2003) Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematology 88, 260-267.
7. O'Brien S.G., Guilhot F., Larson R., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R. & Druker B.J.; IRIS Investigators. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. New England Journal of Medicine 348, 994-1004.
8. O'Hare T., Pollock R., Stoffregen E.P., Keats J.A., Abdullah O.M., Moseson E.M., Rivera V.M., Tang H., Metcalf C.A. 3rd, Bohacek R.S., Wang Y., Sundaramoorthi R., Shakespeare W.C., Dalgarno D., Clackson T., Sawyer T.K., Deininger M.W. & Druker B.J. (2004) Inhibition of wild type and mutant BCR-ABL by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104, 2532-2539.
9. Sawyers C.L. (2003) Resistance to imatinib: more and more mutations. Blood 102, 4-5.
10. Shah N.P., Nicoll J.M., Nagar B., Gorve M.E., Paquette R.L., Kuriyan J. & Sawyers C.L. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor (STI 571) in chronic phase and blast crisis chronic myeloid leukaemia. Cancer Cell 2, 102-117.
11. Tipping A.J., Mahon F.X., Zafirides G., Lagarde V., Goldman J.M. & Melo J.V. (2002) Drug responses of imatinib mesylate-resistant cells: synergist imatinib with other chemotherapeutic drugs. Leukemia 16, 2349-2357.
12. Topaly J., Keller W.J. & Freuhauf S. (2002) Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. British Journal of Haematology 119, 3-14.